8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 8, 2026·SEC
iBio, Inc.(IBIO)Earnings, Financials & Key Ratios
IBIO•NASDAQ
$1.67
Price updated Jun 27, 2026
AboutiBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Show more
- Revenue$400K+77.8%
- EBITDA-$17M-13.6%
- Net Income-$18M+26.2%
- EPS (Diluted)-1.75+73.1%
- Gross Margin100%
- EBITDA Margin-4369%+36.1%
- Operating Margin-4650.5%+37.1%
- Net Margin-4594.25%+58.5%
- ROE-101.52%+25.2%
IBIO Price & Volume
iBio, Inc. (IBIO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Capital Dilution Masks Operational Revenue Volatility
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- iBio's business model remains characterized by erratic, project-dependent revenue streams that fail to cover the company's substantial R&D and SG&A overhead, which totaled $8.4 million in 2026Q3 alone.
- While recent equity-based capital raises have bolstered the cash position to $47.6 million, the company's $354.7 million accumulated deficit suggests a long-term structural inability to achieve self-sustaining profitability.
- Investors should monitor whether the company can transition from its current high-burn, dilution-reliant model toward a stable commercial foundation, as current metrics indicate significant ongoing liquidity risks.
Verdict Logic
the company's inability to generate positive free cash flow, combined with a $354.7 million accumulated deficit, suggests that the current reliance on equity dilution to fund a $5.9 million quarterly operating loss is unsustainable.
IBIO Growth Metrics
iBio, Inc. (IBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.2%
5 Years-24.57%
3 Years-40.34%
TTM-20%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-31.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM75.31%
Return on Capital
10 Years-46.04%
5 Years-57.02%
3 Years-76.54%
Last Year-88.64%
IBIO Recent Earnings
iBio, Inc. (IBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.07-16.7%
$0.06
Rev
—
$20,000
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.09-12.5%
$0.08
Rev
—
$50,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.11-57.1%
$0.07
Rev
$100,000+200.0%
$33,333
Q4 2025
Sep 5, 2025Metric
Actual
Est
EPS
$0.31+20.5%
$0.39
Rev
$200,000+100.0%
$100,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.07vs $0.06-16.7% | —vs $20,000 |
| Q1 2026 | Feb 10, 2026 | $0.09vs $0.08-12.5% | —vs $50,000 |
| Q4 2025 | Nov 12, 2025 | $0.11vs $0.07-57.1% | $100,000vs $33,333+200.0% |
| Q4 2025 | Sep 5, 2025 | $0.31vs $0.39+20.5% | $200,000vs $100,000+100.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for iBio, Inc. (IBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.67 | $26.37M | -0.95 | 77.78% | -4594.25% | -101.52% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — |
Compare IBIO vs Peers
iBio, Inc. (IBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IBIO SEC Filings & Documents
iBio, Inc. (IBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IBIO Frequently Asked Questions
iBio, Inc. (IBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is iBio, Inc.'s revenue?
iBio, Inc. (IBIO) reported $0.3M in revenue for fiscal year 2025. This represents a 67% decrease from $0.9M in 2007.
How fast is iBio, Inc. growing?
iBio, Inc. (IBIO) grew revenue by 77.8% over the past year. This is strong growth.
Is IBIO profitable?
iBio, Inc. (IBIO) reported a net loss of $27.6M for fiscal year 2025.
Dividend & Returns
What is IBIO's return on equity?
iBio, Inc. (IBIO) has a return on equity (ROE) of -101.5%. Negative ROE indicates the company is unprofitable.
What is iBio, Inc.'s free cash flow?
iBio, Inc. (IBIO) had negative free cash flow of $22.2M in fiscal year 2025, likely due to heavy capital investments.